RT Journal Article
SR Electronic
T1 A novel comprehensive Tuberculosis (TB) control programme methodology based on the nexus of participatory action research inspired public health and precision treatment approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.02.23300347
DO 10.1101/2024.01.02.23300347
A1 Shirsajit Mitra
A1 Partha Jyoti Saikia
A1 Anuja Dutta
A1 Rupam Das
A1 Gokul Das
A1 Tutumoni Baishya
A1 Chayanika Das
A1 Tulika Sarma
A1 Sonali Das
A1 Lekhika Pathak
A1 Bikul Das
YR 2024
UL http://medrxiv.org/content/early/2024/01/04/2024.01.02.23300347.abstract
AB Tuberculosis is emerging as a major global health issue for the under-developed regions across the world including India’s North East. Importantly, the incidence of multidrug-resistant (MDR) strain of Mycobacterium tuberculosis (MTB), the causative agent of TB is increasing. Furthermore, the disease is associated with stigma, and therefore people’s wholehearted participation in care, and research support is lacking. Here, we report the development of novel research methodologies through a process of participatory action research (PAR) in India’s Northeast region (NER). The region is economically and socially underdeveloped having approximately 10% higher incidences of TB cases reported than the rest of the country. We have taken an indigenous knowledge system (IKS) based PAR approach, where a century-old local philosophy, Vedic altruism (Jiva Upakara Cikitsha Tantra) has been integrated into our research. Our goal has been to integrate philosophy, clinical care, and the latest clinical, microbiology, and cell biology research tools into one cohesive “knowledge emergence” hub, and then connect it with world’s outstanding research hubs to develop a global PAR against TB. Through this unique PAR-based approach, we were able to identify the stem cell niche as an important factor in TB dormancy, reactivation and MDR evolution. Importantly, we also discovered a natural aerosol-based TB vaccination mechanism. In this paper, we describe various methodologies that we have established as a part of the IKS/PAR-based TB research process. These methodologies include the PAR-based clinical care and monitoring, isolation of live MTB from the peripheral blood and bone marrow-derived progenitor cells, culture and drug-sensitivity test, the challenge of MTB DNA extraction and whole genome sequencing (WGS) from a small population of MTB intracellular to stem cells. We have also developed methodologies to detect viable but non culturable (VBNC) MTB of smear-negative pulmonary TB patients, as well as patients suffering from non-tuberculosis mycobacterium (NTM) infections. These methodologies now enable us to detect patients with an early stage of MDR evolution and compensatory mutation by isolating MTB intracellular to circulating progenitor cells. Importantly, the PAR setup now enables us to collaborate with the world’s leading scientific communities to further our knowledge of TB pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by KaviKrishna Foundation, Sualkuchi, Assam (SM, LP, PS)(KKL/2021-3_MTB), (BD)(KKL/2013-1_MTB); Bill and Melinda Gates Foundation-Grand Challenges Exploration Initiative (2009-2013) (BD); Department of Biotechnology (DBT), Govt. of India (BD) (BT/PR22952/NER/95/572/2017) and KaviKrishna USA Foundation, Lincoln, MA (BD) (KUF/2019-ASC-BD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical study was approved by KaviKrishna Clinical Research and Institutional Ethics Committee. Necessary consents from the patient subjects of Sualkuchi-Hajo area was taken prior to induction for the clinical study. The in-vivo and and stem cell research based studies were approved by the Institutional committee for stem cell research (ICSCR), KaviKrishna and Institutional Bio-safety committee (IBSC), KaviKrishna.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes